FOR IMMEDIATE RELEASE

Aureon Biosciences partners with Men’s Health Network to support its newly created MHN Minority and Underserved Prostate Cancer Fund

Prostate cancer fund to provide information to minority and underserved men and their families

WASHINGTON, D.C., September 1, 2010 – In honor of Prostate Cancer Awareness Month this September, Aureon Biosciences has pledged to donate a portion of the proceeds generated from all of its prognostic tests ordered in September to support the MHN Minority and Underserved Prostate Cancer Fund.

The fund was created to provide important information to minority and underserved men and their families so they can make more informed treatment decisions.

“The fund’s goal and purpose is to reach men who need the information the most,” said Scott Williams, Vice President of Men’s Health Network. “We are proud to partner with Aureon on this critical undertaking.”

To realize its goal, the fund will promote a greater understanding of prostate cancer amongst men and their families, encourage discussions about risk assessment, and support MHN’s Healthy Sunday initiative. The fund will also help men and their families combat the disease by offering information about new technologies and tests that will enable them to make more informed decisions.

“We believe that supplying men and their loved ones with as much data as possible is critical to making informed decisions and fighting prostate cancer,” said Jason Alter, Ph.D. Vice President of Marketing at Aureon. “This fund will provide new resources to help men make the best decision for themselves and their families.”

Aureon has pledged to donate a portion of the proceeds generated for every Prostate Px+ and Post-Op Px prognostic test ordered during the month of September.

Prostate Px+ is a prognostic test that utilizes biopsy tissue “to help patients who have been diagnosed with prostate cancer, but have not yet undergone treatment.” Prostate Px+ provides patients with a more comprehensive analysis of their tissue and assigns them a risk score between 1 and 100 to help give them a clearer and more accurate understanding of their disease.

Post-Op Px is a prognostic test that was developed to help patients who recently had surgery for their prostate cancer. Post-Op Px analyzes each patient’s prostatectomy tissue and provides them with a risk score between 1 and 100 to help them better understand and predict their individual risk for recurrence.

To learn more visit: www.menshealthnetwork.org/minorityprostatefund.html

About Aureon (www.aureon.com)
Aureon Biosciences is a life science company dedicated to enabling the advancement of predictive and personalized cancer treatment options. Aureon employs a unique Systems Pathology approach and provides personalized test results by analyzing a patient's existing biopsy sample using molecular diagnostics, sophisticated tissue-based image analysis and advanced mathematics.

**About Men's Health Network (www.menshealthnetwork.org)**

Men's Health Network (MHN) is a national non-profit organization whose mission is to reach men and their families where they live, work, play, and pray with health prevention messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation.